Typefaces

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Myriad Genetics, Inc.

Retrieved on: 
Monday, October 14, 2019

Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN ) investors who purchased securities between September 2, 2016 and August 13, 2019, inclusive (the Class Period).

Key Points: 
  • Glancy Prongay & Murray LLP (GPM) reminds investors of the upcoming November 26, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN ) investors who purchased securities between September 2, 2016 and August 13, 2019, inclusive (the Class Period).
  • Myriad also disclosed that the FDA requested changes to the GeneSight test offering after Myriad had provided the FDA with clinical evidence and other information to support GeneSight Psychotropic.
  • If you purchased or otherwise acquired Myriad securities during the class period, you may move the Court no later than November 26, 2019 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

HGGC Completes Acquisition of Monotype Imaging Holdings Inc.

Retrieved on: 
Friday, October 11, 2019

Monotype Imaging Holdings Inc. today announced the completion of the transaction under which HGGC, LLC (HGGC), a leading middle market private equity firm, has acquired all of the outstanding shares of Monotype for $19.85 per share in cash, representing an aggregate equity value of approximately $825 million.

Key Points: 
  • Monotype Imaging Holdings Inc. today announced the completion of the transaction under which HGGC, LLC (HGGC), a leading middle market private equity firm, has acquired all of the outstanding shares of Monotype for $19.85 per share in cash, representing an aggregate equity value of approximately $825 million.
  • Rich Lawson, CEO and Co-Founder at HGGC, said, Today marks the beginning of the next exciting chapter for Monotype.
  • Monotype is a trademark of Monotype Imaging Inc. registered in the U.S. Patent and Trademark Office and may be registered in certain other jurisdictions.
  • 2019 Monotype Imaging Holdings Inc. All rights reserved.

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Myriad Genetics, Inc.– MYGN

Retrieved on: 
Tuesday, October 8, 2019

NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Myriad Genetics, Inc. (NASDAQ: MYGN) from September 2, 2016 through August 13, 2019 inclusive (the Class Period).

Key Points: 
  • NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Myriad Genetics, Inc. (NASDAQ: MYGN) from September 2, 2016 through August 13, 2019 inclusive (the Class Period).
  • The lawsuit seeks to recover damages for Myriad Genetics, Inc. investors under the federal securities laws.
  • To join the class action, go to http://pawarlawgroup.com/cases/myriad-genetics-inc/ or call Vik Pawar, Esq.
  • toll-free at 888-589-9804 or email [email protected] for information on the class action.

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting

Retrieved on: 
Tuesday, October 8, 2019

The Myriad Foresight Carrier Screen is designed to maximize detection of at-risk couples for serious, prevalent, and clinically-actionable conditions.

Key Points: 
  • The Myriad Foresight Carrier Screen is designed to maximize detection of at-risk couples for serious, prevalent, and clinically-actionable conditions.
  • Foresight has a rigorous disease selection that focuses on 175+ conditions that provides meaningful information to patients.
  • Myriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.
  • For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com .

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Myriad Genetics, Inc. Investors

Retrieved on: 
Monday, October 7, 2019

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN ) securities between September 2, 2016 and August 13, 2019, inclusive (the Class Period).

Key Points: 
  • Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Myriad Genetics, Inc. (Myriad or the Company) (NASDAQ: MYGN ) securities between September 2, 2016 and August 13, 2019, inclusive (the Class Period).
  • Myriad investors have until November 26, 2019 to file a lead plaintiff motion.
  • Investors suffering losses on their Myriad investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Shareholder Alert: Robbins Arroyo LLP Announces Myriad Genetics, Inc. (MYGN) Sued for Misleading Shareholders

Retrieved on: 
Friday, October 4, 2019

Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Myriad Genetics, Inc. (NASDAQ: MYGN) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between September 2, 2016 and August 13, 2019.

Key Points: 
  • Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Myriad Genetics, Inc. (NASDAQ: MYGN) filed a class action complaint for alleged violations of the Securities Exchange Act of 1934 between September 2, 2016 and August 13, 2019.
  • Myriad Genetics is a molecular diagnostic company that develops and markets prognostic medicine tests.
  • Myriad's products include GeneSight, a DNA genotyping test that aids in psychotropic drug selection for depressed patients and ForeSight, a carrier screening test.
  • Myriad also neglected to inform investors that acquiring Counsyl's product ForeSight could incur risk of suffering from lower reimbursements, which could materially impact Myriad's revenue.

Wikki Stix Celebrates Success of 2nd Annual Unplugged Play Day

Retrieved on: 
Thursday, October 3, 2019

"Kids have lost the art of playing," said Kem Clark, President of the Wikki Stix Co. "They watch, rather than DO!

Key Points: 
  • "Kids have lost the art of playing," said Kem Clark, President of the Wikki Stix Co. "They watch, rather than DO!
  • Outside play can involve tossing a frisbee around or playing kickball, while indoor fun can involve board games, cards, or an activity like Wikki Stix.
  • Moms from all over the country purchased an at-home Wikki Stix Play Day, providing creative hands-on fun for more than 5,000 children nationwide.
  • Over 100 toy stores also offered a Wikki Stix Play Day in their facilities.

Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Myriad Genetics, Inc. (NASDAQ: MYGN) and Encourages Myriad Genetics Investors to Contact the Firm

Retrieved on: 
Tuesday, October 1, 2019

Investors have until November 26, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until November 26, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On September 1, 2016, Myriad announced the completion of its acquisition of Assurex Health, Inc. (Assurex).
  • On July 31, 2018, Myriad announced that it had closed its acquisition of Counsyl, Inc. (Counsyl).
  • This acquisition provided Myriad with two new productsForeSight and Preludein the expanded carrier screening and non-invasive prenatal testing markets, respectively.

Myriad Genetics Expands Board of Directors with Two Additional Members

Retrieved on: 
Wednesday, September 25, 2019

Ms. Reitan has extensive expertise in the healthcare insurance industry, having spent more than 32 years in the Blues system.

Key Points: 
  • Ms. Reitan has extensive expertise in the healthcare insurance industry, having spent more than 32 years in the Blues system.
  • He is an experienced board member and currently serves on the board at Cellworks Group Inc. and Intervention Insights, Inc.
  • We are delighted to welcome Colleen and Lee to the Myriad Board, said Mark C. Capone, President and CEO of Myriad.
  • Myriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.

Cambria Hotels Plans Midwest Expansion

Retrieved on: 
Tuesday, September 24, 2019

Slated to be the first Cambria in Missouri and the third in Indiana, these hotels will continue to drive the upscale brand's rapid U.S. expansion when they open in 2021.

Key Points: 
  • Slated to be the first Cambria in Missouri and the third in Indiana, these hotels will continue to drive the upscale brand's rapid U.S. expansion when they open in 2021.
  • "These new agreements are just the latest example of developer interest in the Cambria brand," said Mark Shalala, vice president, franchise development, upscale brands, Choice Hotels.
  • Cambria Hotels is rapidly expanding in major U.S. cities, with hotels open in Chicago, New York City, Pittsburgh, Washington, D.C., and Los Angeles.
  • A copy of the Franchise Disclosure Document can be obtained through contacting Choice Hotels International at 1 Choice Hotels Circle, Suite 400,Rockville, MD20850, [email protected] .